**Amendments to the Claims:**

*This listing of claims will replace all prior versions, and listings, of claims in the application:*

**Listing of Claims:**

1. (Previously presented) A compound according to the general Formula (I)




(I)

the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and prodrugs thereof, wherein :

| | |
|---|---|
| n | is an integer, equal to 1; |
| m | is an integer, equal to 1; |
| p | is an integer equal to 1 or 2; |
| q | is an integer equal to 0; |
| Q | is O; |
| X | is a covalent bond; |
| each $R^3$ | independently from each other, is hydrogen or alkyl ; |
| each $R^1$ | independently from each other, is selected from the group of $Ar^1$, $Ar^1$-alkyl and di($Ar^1$)-alkyl ; |
| $R^2$ | is $Ar^2$; |
| Y | is a covalent bond or a bivalent radical of formula -C(=O)-, $-SO_2-$ >C=CH-R or >C=N-R, wherein R is H , CN or nitro ; |

each Alk represents, independently from each other, a covalent bond ; a bivalent straight or branched, saturated or unsaturated hydrocarbon radical having from 1 to 6 carbon atoms ; or a cyclic saturated or unsaturated hydrocarbon radical having from 3 to 6 carbon atoms ; each radical optionally substituted on one or more carbon atoms with one or more , phenyl, halo, cyano, hydroxy, formyl and amino radicals;

L is selected from the group of hydrogen, alkyl, alkyloxy, alkyloxyalkyloxy, alkylcarbonyloxy, alkyloxycarbonyl, mono- and di(alkyl)amino, mono- and di(alkyloxycarbonyl)amino, mono- and di(alkylcarbonyl)amino, mono-and di($Ar^3$)amino, mono-and di($Ar^3$alkyl)amino, mono-and di($Het^2$)amino, mono-and di($Het^2$alkyl)amino, alkylsulfanyl, adamantyl, $Ar^3$, $Ar^3$-oxy, $Ar^3$carbonyl, $Het^2$, Het-oxy and $Het^2$carbonyl;

$Ar^1$ is phenyl, optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of halo, alkyl, cyano, aminocarbonyl and alkyloxy ;

$Ar^2$ is naphthalenyl or phenyl, each optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of halo, nitro, amino, mono- and di(alkyl)amino, cyano, alkyl, hydroxy, alkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl and mono- and di(alkyl)aminocarbonyl ;

$Ar^3$ is naphthalenyl or phenyl, optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of alkyloxy, $Ar^1$carbonyloxyalkyl, $Ar^1$alkyloxycarbonyl, $Ar^1$alkyloxyalkyl, alkyl, halo, hydroxy, pyridinyl, morpholinyl, pyrrolidinyl, imidazo[1,2-*a*]pyridinyl, morpholinylcarbonyl, pyrrolidinylcarbonyl, amino and cyano;

$Het^2$ is a monocyclic heterocyclic radical selected from the group of pyrrolidinyl, dioxolyl, imidazolidinyl, pyrazolidinyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, imidazolidinyl, tetrahydrofuranyl, 2H-pyrrolyl, pyrrolinyl, imidazolinyl, pyrazolinyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, furanyl, thienyl, oxazolyl, dioxazolyl, oxazolidinyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, pyridinyl, pyrimidinyl,

pyrazinyl, pyridazinyl and triazinyl ;
or a bicyclic heterocyclic radical selected from the group of 2,3-dihydro-benzo[1,4]dioxine, octahydro-benzo[1,4]dioxine, benzopiperidinyl, quinolinyl, quinoxalinyl, indolyl, isoindolyl, chromanyl, benzimidazolyl, imidazo[1,2-*a*]pyridinyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl or benzothienyl ;
or the tricyclic heterocyclic radical 8,9-dihydro-4*H*-1-oxa-3,5,7a-triaza-cyclopenta[f]azulenyl ; each radical may optionally be substituted with one or more radicals selected from the group of $Ar^1$, $Ar^1$alkyl, $Ar^1$alkyloxyalkyl, halo, hydroxy, alkyl, piperidinyl, pyrrolyl, thienyl, oxo, alkyloxy, alkylcarbonyl, $Ar^1$carbonyl, mono- and di(alkyl)aminoalkyl, alkyloxyalkyl and alkyloxycarbonyl; and

alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radicals having from 3 to 6 carbon atoms ; optionally substituted on one or more carbon atoms with one or more radicals selected from the group of phenyl, halo, cyano, oxo, hydroxy, formyl and amino.

2. (Previously amended) A compound according to claim 1 wherein :

$R^1$ is $Ar^1$-alkyl;

$R^2$ is $Ar^2$;

Y is a covalent bond or a bivalent radical of formula -C(=O)-, $-SO_2-$, >C=CH-R or >C=N-R, wherein R is CN or nitro ;

each Alk represents, independently from each other, a covalent bond ; a bivalent straight or branched, saturated hydrocarbon radical having from 1 to 6 carbon atoms ; or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms ; each radical optionally substituted on one or more carbon atoms with one or more phenyl, halo and hydroxy radicals;

L is selected from the group of hydrogen, alkyl, alkyloxy, alkyloxyalkyloxy, alkylcarbonyloxy, mono- and di(alkyl)amino, mono- and di(alkyloxycarbonyl)amino, mono- and di(alkylcarbonyl)amino, mono-and di($Ar^3$)amino, mono-and di($Ar^3$alkyl)amino, mono-and di($Het^2$alkyl)amino,

alkylsulfanyl, adamantyl, $Ar^3$, $Het^2$ and $Het^2$carbonyl;

$Ar^1$ is phenyl, optionally substituted with 1 or 2 halo radicals ;$Ar^2$ is naphthalenyl or phenyl, each optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of halo, alkyl and alkyloxy;

$Ar^3$ is naphthalenyl or phenyl, optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of alkyloxy, $Ar^1$alkyloxycarbonyl, $Ar^1$alkyloxyalkyl, alkyl, halo and cyano;

$Het^2$ is a monocyclic heterocyclic radical selected from the group of pyrrolidinyl, dioxolyl, piperidinyl, morpholinyl, piperazinyl, tetrahydrofuranyl, pyrrolyl, imidazolyl, pyrazolyl, furanyl, thienyl, dioxazolyl, oxazolidinyl, isoxazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocyclic radical selected from the group of 2,3-dihydro-benzo[1,4]dioxine, octahydro-benzo[1,4]dioxine, quinoxalinyl, indolyl, chromanyl, benzimidazolyl, imidazo[1,2-*a*]pyridinyl, benzisoxazolyl, benzothiazolyl,benzofuranyl and benzothienyl ; or the tricyclic heterocyclic radical 8,9-dihydro-4*H*-1-oxa-3,5,7a-triaza-cyclopenta[f]azulenyl ; each radical may optionally be substituted with one or more radicals selected from the group of $Ar^1$, $Ar^1$alkyloxyalkyl, halo, alkyl, oxo, alkyloxy, alkylcarbonyl, $Ar^1$carbonyl, mono- and di(alkyl)aminoalkyl, alkyloxyalkyl and alkyloxycarbonyl ; and

alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radicals having from 3 to 6 carbon atoms ; optionally substituted on one or more carbon atoms with one or more radicals selected from the group of phenyl, halo and hydroxy.

3. (Previously presented) A compound according to claim 1, wherein $R^1$ is $Ar^1$methyl and attached to the 2-position or $R^1$ is $Ar^1$ and attached to the 3-position.

4. (Previously presented) A compound according to claim 1, wherein $R^2$-X-C(=Q)-moiety is 3,5-di-(trifluoromethyl) phenylcarbonyl.

5. (Canceled)

6. (Previously presented) A compound according to claim 1, wherein Y is -C(=O)-.

7. (Previously presented) A compound according to claim 1, wherein Alk is a covalent bond.

8. (Previously presented) A compound according to claim 1, wherein L is $Het^2$.

9. (Currently amended) A compound according to claim 1, selected from the group consisting of:

[2R-trans]-{2-benzyl-4-[4-(1-pyrazin-2-yl-pyrrolidin-3-yl)-piperazin-1-yl]-piperidin-1-yl}-(3,5-bis-trifluoromethyl-phenyl)-methanone,



[2R-[2α,4β(S)]]-1-(3-{4-[2-benzyl-1-(3,5-bis-trifluoromethyl-benzoyl)-piperidin-4-yl]-piperazin-1-yl}-pyrrolidin-1-yl)-2,2-dimethyl-propan-1-one,



[2R-[2α,4β(S*)]-{2-benzyl-4-[4-(1-cyclopropanecarbonyl-pyrrolidin-3-yl)-piperazin-1-yl]-piperidin-1-yl}-(3,5-bis-trifluoromethyl-phenyl)-methanone,



[2R-trans]-enantiomer of {2-benzyl-4-[4-(1-cyclopropanecarbonyl-pyrrolidin-3-yl)-piperazin-1-yl]-piperidin-1-yl}-(3,5-bis-trifluoromethyl-phenyl)-methanone,

2R-trans-(2-benzyl-4-{4-[1-(tetrahydro-furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone,



[2R-[2α,4β(R(R))]]-(2-benzyl-4-{4-[1-(tetrahydro-furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone,

[2R-[2α,4β(S(R))]]-(2-benzyl-4-{4-[1-(tetrahydro-furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone,

[2R-trans, R*]-(2-benzyl-4-{4-[1-(furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone,



[2R-[2α,4β(R)]]-(2-benzyl-4-{4-[1-(5-methyl-thiophene-2-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone,



[2R-trans]-(2-benzyl-4-{4-[1-(3-hydroxymethyl-thiophene-2-sulfonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone,



[2R-[2α,4β(S)]]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-dichloro-benzyl)-4-{4-[1-(4-hydroxy-butyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone,



[(2R-trans),(S)]-1-(3-{4-[1-(3,5-bis-trifluoromethyl-benzoyl)-2-(3,4-dichloro-benzyl)-piperidin-4-yl]-piperazin-1-yl}-pyrrolidin-1-yl)-2,2-dimethyl-propan-1-one,



trans-(3,5-bis-trifluoromethyl-phenyl)-[4-{4-[1-(2-chloro-benzoyl)-pyrrolidin-3-yl]-piperazin-1-yl}-2-(3,4-dichloro-benzyl)-piperidin-1-yl]-methanone,



[(2R-trans),(S)]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-dichloro-benzyl)-4-{4-[1-(thiophene-2-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone,



[(2R-trans), (R)]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-dichloro-benzyl)-4-{4-[1-(thiophene-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone,



[(2R-trans), (R)]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-dichloro-benzyl)-4-{4-[1-(furan-2-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone,



[(2R-trans), (S)]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-dichloro-benzyl)-4-{4-[1-(furan-2-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone,

[(2R-trans), (S), (R)]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-dichloro-benzyl)-4-{4-[1-(tetrahydro-furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone,



[(2R-trans), (R)]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-dichloro-benzyl)-4-{4-[1-(pyrazine-2-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone,



[2R-[2α,4β(R*)]]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-difluoro-benzyl)-4-{4-[1-(1-methyl-1H-pyrrole-2-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone,



[2R-[2α,4β(R*(S*))]]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-difluoro-benzyl)-4-{4-[1-(tetrahydro-furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone,



[2R-[2α,4β(S*(S*))]]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-difluoro-benzyl)-4-{4-[1-(tetrahydro-furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone,

[2R-[2α,4β(S*(R*))]]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-difluoro-benzyl)-4-{4-[1-(tetrahydro-furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone,

[2R-[2α,4β(R*(R*))]]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-difluoro-benzyl)-4-{4-[1-(tetrahydro-furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone,

[2R-[2α,4β(S*)]]-(3,5-Bis-trifluoromethyl-phenyl)-(2-(3,4-difluoro-benzyl)-4-{4-[1-(furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone,




[2R-[2α,4β(S*)]]-(3,5-Bis-trifluoromethyl-phenyl)-(2-(3,4-difluoro-benzyl)-4-{4-[1-(pyrazine-2-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone,



[2R-[2α,4β(S*)]]-(3,5-Bis-trifluoromethyl-phenyl)-(2-(3,4-difluoro-benzyl)-4-{4-[1-(4-methyl-[1,2,3]thiadiazole-5-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone, and



cis-(3,5-Bis-trifluoromethyl-phenyl)-(3-phenyl-4-{4-[1-(thiophene-2-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone.



10. (Cancelled)

11. (Canceled)

12. (Canceled)

13. (Currently amended) A method for treating schizophrenia, emesis, anxiety, depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, pain, neurogenic inflammation, asthma, micturition disorders ~~such as urinary incontinence~~ and nociception in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to claim 1.

14. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound according to claim 1.

15. (Previously presented) A process for preparing a pharmaceutical composition as claimed in claim 14, wherein a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as claimed claim 1.

16. (Original) A process for the preparation of a compound of Formula (I") in which an intermediate compound of Formula (II) is reacted with an intermediate compound of Formula (III), wherein the radicals $R^2$, X, Q, $R^1$, m, n, p and q are as defined in claim 1.



(II) (III) (I")

17. (Withdrawn) A process for the preparation of a compound of Formula (I') in which a final compound of Formula (I") is reductively hydrogenated, wherein the radicals $R^2$, X, Q, $R^1$, m, n, p and q are as defined in claim 1.



(I") (I')

18. (Withdrawn) A process for the preparation of a compound according to Formula (I') comprising the consecutive steps of

1) obtaining a compound of Formula (I") according to claim 16;

2) obtaining a compound of Formula (I') according to claim 17.